UK OPTIMUM/MUKnine: Dara-VRd in Ultra-High‒Risk NDMM
UK OPTIMUM/MUKnine: Phase II Trial of Intensified Dara-VRd Consolidation After ASCT in Ultra-High‒Risk Newly Diagnosed Multiple Myeloma and Primary Plasma Cell Leukemia

Released: December 15, 2022

Expiration: December 14, 2023

Activity

Progress
1
Course Completed